Serum Institute of India 
Welcome,         Profile    Billing    Logout  
 25 Products   1 Disease  25 Products   33 Trials   4033 News 
75 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ErepoXen (polysialylated erythropoietin) / Xenetic Biosci, Serum Institute of India, Pharmsynthez
ACTRN12613000504718: Dose finding study for Polysialylated Erythropoietin (PSA-EPO) in Chronic Kidney Disease (CKD) subjects

Recruiting
2
90
 
Xenetic Biosciences PLC, Xenetic Biosciences PLC
Anaemia in Chronic Kidney Disease
 
 
ErepoXen1: Dose finding study for Polysialylated Erythropoietin (PSA-EPO) in Chronic Kidney Disease (CKD) subjects

Recruiting
2
90
Australia, New Zealand
ErepoXen (polysialylated erythropoietin)
Xenetic Biosciences
Chronic Kidney Disease
 
 
R-vac (rubella vaccine) / Serum Institute of India
NCT06879327: Infant Malaria Vaccine Schedule Optimization

Recruiting
2
1200
RoW
R21 Matrix-M (R21/MM) Malaria Vaccine, Placebo, Hexavalent Vaccine, HEXASIIL, Pneumococcal Polysaccharide Conjugate Vaccine, PNEUMOSIL, Rotavirus, Live Attenuated (Oral) Vaccine, ROTASIIL, Measles and Rubella Vaccine, Meningococcal A conjugate vaccine, MenAfriVac, Yellow Fever vaccine, Typhoid Conjugate vaccine
PATH, Serum Institute of India PVT LTD (SII), Agilis, Pharmassist Ltd, MCT-CRO, Cytespace
Malaria Vaccines
11/27
11/27
Tetanus Antitoxin / Serum Institute of India
2019-002706-46: A Clinical Study to Assess the Safety and Immunogenicity of the Tetanus, Diphtheria and Pertussis Vaccine SIIPL Tdap in Comparison with Boostrix® in Healthy Adults, Adolescents and Children

Not yet recruiting
2/3
1332
Europe
SIIPL Tdap, Tdap, Suspension for injection in pre-filled syringe, Boostrix
Vakzine Projekt Management GmbH, Serum Institute of India Pvt. Ltd.
Active booster immunization against tetanus, diphtheria and pertussis, The vaccine is given to healthy individuals to prevent the tetanus, diphtheria and whooping cough diseases, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
ACTRN12620000848909: A Clinical Trial to Assess the safety and immunogenicity of a combined Tetanus, Diphtheria, Acellular Pertussis and Poliomyelitis Vaccine (SIIPL Tdap-IPV) compared with Boostrix-IPV in Healthy Adults, Adolescents and Children

Terminated
1/2
204
 
Serum Institute of India Pvt Ltd, Serum Institute of India Pvt Ltd
Tetanus, Diphtheria, Pertussis, Polio
 
 
Tresivac (measles, mumps & rubella vaccine live) / Serum Institute of India
MEQ00064, NCT05794230: Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa

Active, not recruiting
3
1528
RoW
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, MenACYW conjugate vaccine - MenQuadfi™, Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Menactra®, Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV), BIOPOLIO® B1/3, Pneumoccocal Vaccine, Prevnar 13®, Measles, Mumps, and Rubella Vaccine live (MMR), TRESIVAC® PFS, DTwP-HepB-Hib-IPV vaccine, EasySix™, DTaP-IPV-Hib-HepB vaccine, Hexaxim®, Hepatitis A vaccine, Biovac®-A, Rotavirus vaccine, RotaTeq®, Typhoid conjugate vaccine (TCV), Typbar TCV®, Measles vaccine, MeasBio®, Varicella vaccine live, VARIPED®, ONVARA®, OMZYTA®, Avaxim® 80 U Pediatric
Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation, Healthy Volunteers
12/25
12/25
MenAfriVac (meningococcal A conjugate vaccine) / Serum Institute of India
NCT03746665: Maternal Immunization With MenAfriVac™

Active, not recruiting
3
200
RoW
meningococcal serogroup A conjugate vaccine, MenAfriVac™.
London School of Hygiene and Tropical Medicine, Public Health England, Department of State for Health and Social Welfare, The Gambia, World Health Organization, University of Cambridge, Stanford University
Meningitis, Meningococcal
10/20
08/21
VPM1002 / SAKK, Serum Institute of India
NCT04387409 / 2020-001376-15: Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic

Active, not recruiting
3
59
Europe
VPM1002, Placebo
Vakzine Projekt Management GmbH, FGK Clinical Research GmbH
Infection, Respiratory Tract
05/21
05/21
VPM1002, NCT04351685: Evaluation of Efficacy and Safety of in Comparison to BCG in Prevention of Tb Infection in Infants

Completed
3
6940
RoW
VPM1002, BCG SII
Serum Institute of India Pvt. Ltd., Vakzine Projekt Management GmbH
Mycobacterium Tuberculosis Infection
10/24
10/24
NCT03152903: Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence

Completed
2/3
2000
RoW
VPM1002 (Recombinant BCG Vaccine), Placebo
Serum Institute of India Pvt. Ltd.
Prevention of TB Recurrence
12/23
12/23
SAKK 06/19, NCT04630730: Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Active, not recruiting
2
46
Europe
Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC), VPM1002BC, Atezolizumab, Tecentriq™, Cisplatin, Platinol®, Gemcitabine, Gemzar ®
Swiss Group for Clinical Cancer Research
Bladder Cancer
06/26
06/30
SAKK 06/14, NCT02371447 / 2014-005330-58: VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer

Completed
1/2
39
Europe
VPM1002BC, Mycobacterium bovis BCG∆ureC::Hly+, VPM1002
Swiss Group for Clinical Cancer Research
Bladder Cancer
10/19
03/23
NCT05539989: Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa

Withdrawn
1/2
480
RoW
VPM1002 Vaccine, BCG Vaccine, Placebo
International Maternal Pediatric Adolescent AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH)
Tuberculosis, HIV Infections
07/27
07/27
NeuCeptin (trastuzumab biosimilar) / NeuClone, Serum Institute of India
ACTRN12618001657213: A clinical trial to compare the rate of blood clearance and safety of a biosimilar, to the original Herceptin drug, in healthy male volunteers.

Active, not recruiting
1
111
 
NeuClone Pty Ltd, NeuClone Pty Ltd
Her2 positive breast cancer, Her2 positive gastric cancer
 
 
NeuLara (ustekinumab biosimilar) / NeuClone, Serum Institute of India
ACTRN12619001473156: A Phase 1 Single Dose Study to Assess the Pharmacokinetics and Safety of the Biosimilar Ustekinumab Healthy Volunteers

Recruiting
1
210
 
NeuClone Proprietary Limited, NeuClone Proprietary Limited
Plaque Psoriasis
 
 
meningococcal groups ACYWX conjugate vaccine (NmCV-5) / PATH, Serum Institute of India
NCT05093829: Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine

Completed
3
1325
RoW
NmCV-5, MenACWY-TT, Nimenrix
Emory University, National Institute of Allergy and Infectious Diseases (NIAID)
Meningitis
03/23
02/25
NCT05739292: Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old

Completed
1
60
RoW
EuNmCV-5, Meningococcal(Groups A, C, W-135, X, and Y) Conjugate Vaccine, Menveo, Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine
EuBiologics Co.,Ltd
Infection, Meningococcal
05/23
10/23
R21/Matrix-M / University of Oxford, Serum Institute of India
IMVACS, NCT06860178: Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa

Not yet recruiting
4
40000
RoW
Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months
Epicentre, R-Evolution Worldwide, CNRST Burkina Faso, USTTB Mali, Liverpool School of Tropical Medicine
Malaria Vaccine
05/26
12/27
COSAV-R21, NCT07038837: Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in Chad

Not yet recruiting
4
70000
RoW
"Synchronised" arm (intervention)
Epicentre, Epicentre, Paris, France., Chad Ministry of Public Health Expanded Programme on Immunisation (EPI), Chad Ministry of Public Health National Malaria Control Programme (NMCP), Liverpool School of Tropical Medicine
Malaria Infection, Malaria Vaccines
12/26
06/28
MVDA, NCT06068530: Mass Vaccine and Drug Administration, Bangladesh

Recruiting
4
10000
RoW
DHA/piperaquine and a SLD-PQ, Study vaccine R21/Matrix-M™
University of Oxford
Plasmodium Falciparum Malaria
02/28
02/28
NCT04704830: R21/Matrix-M in African Children Against Clinical Malaria

Active, not recruiting
3
4800
Europe
R21/Matrix-M, Rabies vaccine or Hepatitis A vaccine
University of Oxford, Institut de Recherche en Sciences de la Sante - Clinical Research Unit of Nanoro (IRSS-URCN), Nanoro, Burkina Faso, Institut de Recherche en Sciences de la Sante-Direction Regionale de l'Ouest, Malaria Research and Training Center, Bamako, Mali, KEMRI-Wellcome Trust Collaborative Research Program, Ifakara Health Institute Clinical Trial Facility, Bagamoyo Research and Training Centre, PO Box 74, Bagamoyo, Tanzania, London School of Hygiene and Tropical Medicine
Malaria
03/23
03/26
2018-004391-34: A clinical trial to assess the safety, immune response, and protection against infection of novel malaria vaccines.

Not yet recruiting
2
82
Europe
R21, Matrix-M, Solution for injection
University of Oxford
Plasmodium falciparum infection, Malaria, Diseases [C] - Parasitic Diseases [C03]
 
 
NCT03947190: A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults

Terminated
2
80
RoW
R21/Matrix-M, ChAd63/MVA ME-TRAP, intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge
University of Oxford, Kenya Medical Research Institute, European and Developing Countries Clinical Trials Partnership (EDCTP)
Malaria,Falciparum
02/23
02/23
R21/Matrix-M, NCT05252845: Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults

Completed
2
127
RoW
R21/Matrix-M vaccination, DHA-PIP, PQ
University of Oxford
Malaria,Falciparum
06/23
09/23
NCT03896724: Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso

Completed
1/2
450
RoW
R21 adjuvanted with 25mcg Matrix-M, Rabies Vaccine, R21 adjuvanted with 50mcg Matrix-M
University of Oxford, Institut de Recherche en Sciences de la Sante - Clinical Research Unit of Nanoro (IRSS-URCN), European and Developing Countries Clinical Trials Partnership (EDCTP)
Malaria,Falciparum
07/23
07/23
NCT05155579: Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

Active, not recruiting
1
590
Europe, RoW
R21/Matrix-M - single vial formulation, R21/Matrix-M - two vial formulation, Licensed vaccine - Measles-rubella, Licensed vaccine - Yellow fever, Licensed vaccine - Pentavalent (diphtheria, tetanus, pertussis, hepatitis B and Hib), Licensed vaccine - Oral Polio Vaccine (OPV), Licensed vaccine - Rotavirus, Licensed vaccine - Pneumococcal vaccine, Licensed vaccine - Inactivated Polio Vaccine (IPV)
University of Oxford, Malaria Research and Training Center, Bamako, Mali
Malaria
05/25
05/25
NCT06320535: A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™

Recruiting
1
36
Europe
R21/Matrix M™ (Group 1), R21/Matrix M™ (Group 2), R21/Matrix M™ (Group 3), Fine needle aspiration (FNA)
University of Oxford, Bill and Melinda Gates Foundation, University Hospitals Bristol and Weston NHS Foundation Trust
Malaria,Falciparum
06/26
06/27
NCT05385510: Assessment of Safety and Immunogenicity of R21/Matrix-M™ in African Children Living With HIV

Active, not recruiting
1
120
RoW
R21/Matrix-M™
University of Oxford, MRC/UVRI and LSHTM Uganda Research Unit
Malaria
09/25
09/25
NCT06507605: Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults

Active, not recruiting
1
240
RoW
R21, Pfs230D1-CRM197, Pfs230D1-EPA, Matrix-M
Serum Institute of India Pvt. Ltd., National Institute of Allergy and Infectious Diseases (NIAID)
Prevention of Malaria Transmission and Clinical Malaria
10/25
10/25
VAC093, NCT06958198: A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)

Not yet recruiting
1
56
RoW
R21, RH5.1, R78C, Matrix-M™
University of Oxford, Institut de Recherche en Sciences de la Sante, Burkina Faso, European and Developing Countries Clinical Trials Partnership (EDCTP), Wellcome Trust
Malaria,Falciparum
10/26
10/26
NCT05357560: A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21

Active, not recruiting
1
107
RoW
Matrix-M with RH5.2 VLP and/or R21
University of Oxford, European and Developing Countries Clinical Trials Partnership (EDCTP), Medical Research Council Unit, The Gambia
Malaria, Plasmodium Falciparum
06/25
06/25
NCT07009847: An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine

Not yet recruiting
N/A
2308
RoW
Case control study of clinical malaria, Case control study of severe malaria, Case control study of death (all cause)
Serum Institute of India Pvt. Ltd.
Malaria,Falciparum, Morality
10/26
12/26
Pneumosil (10-valent pneumococcal conjugate vaccine) / Serum Institute of India
FPCV, NCT03489018: The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants

Completed
4
2100
RoW
PCV10, Synflorix (GlaxoSmithKline plc.), 10-valent pneumococcal conjugate vaccine, PCV13, Prevnar 13 (Pfizer Inc.), 13-valent pneumococcal conjugate vaccine, Prevnar13
London School of Hygiene and Tropical Medicine, University College, London, KEMRI-Wellcome Trust Collaborative Research Program, Bill and Melinda Gates Foundation, National Institute of Health Research (NIHR) Mucosal Pathogens Research Unit (MPRU), Wellcome Trust
Pneumococcal Infection, Streptococcus Pneumoniae Infection, Invasive Pneumococcal Disease, Protection Against
09/22
11/24
fPCV, NCT05175014: Mass Campaigns With Fractional Dose Pneumococcal Vaccines in Sub-Saharan Africa

Completed
4
44618
RoW
PCV10 full dose, PCV10 fractional dose
Epicentre, LSHTM, Kenya Medical Research Institute, Universite Abdou Moumouni de Niamey, Niger
Pneumococcal Carriage
03/23
10/23
OPTIMAL, NCT06817421: Opportunistic Pneumococcal Immunisation Trial in MALnutrition

Not yet recruiting
4
264
RoW
Pneumococcal conjugate vaccine, Typhoid conjugate vaccine
Nick Fancourt, Murdoch Childrens Research Institute, The University of Western Australia, University of Edinburgh, Timor-Leste Ministry of Health
Severe Acute Malnutrition in Childhood, Pneumococcal Disease, Pneumococcal Vaccines, Pneumococcal Infection, Pneumonia in Children
12/27
02/29
NCT06116591: A Phase 2 Study to Learn About a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers

Completed
2
105
Europe
mPnC candidate, mPnC control
Pfizer
Healthy Participants
05/24
05/24
PNEUMOSIL, NCT05140720: Assess the Safety and Immunogenicity of ® Vaccine in Healthy Vietnamese Children, 6 Weeks to 24 Months of Age

Not yet recruiting
N/A
300
NA
PNEUMOSIL®
Vabiotech, Vietstar Biomedical Research
Streptococcus Pneumonia, Vaccine Preventable Disease
02/22
06/22
PCV1+1_FU, NCT04275284: Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children

Completed
N/A
600
RoW
PCV10, Synflorix, PCV13, Prevnar13
University of Witwatersrand, South Africa
Pneumonia, Meningitis
12/22
12/22
Covovax (NVX-CoV2373) / Novavax, Serum Institute of India
ACTRN12622000238774: A randomised trial to evaluate the immune response of COVID-19 vaccines in adults and adolescents

Recruiting
4
1325
 
The Kids Research Institute Australia, National Health and Medical Research Council (NHMRC), Snow Medical Research Foundation
COVID-19
 
 
2022-000905-29: Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after treatment with monoclonal antibodies Cinetica tempoRale dei marcatori di risposta anticorpale e cEllulare e relativo impatto della rivacciNazione in pazienti guariti dalla COVID-19 dopo trattamento con anticoRpi monoclonali

Not yet recruiting
4
150
Europe
Evusheld, Xevudy, Comirnaty, Spikevax, Nuvaxovid, [-], Solution for injection, Concentrate for solution for infusion, Dispersion for injection, Evusheld, Xevudy, Comirnaty, Spikevax, Nuvaxovid
ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI"
Covid-19 infection Infezione da Covid-19, Covid-19 infection Infezione da Covid-19, Diseases [C] - Virus Diseases [C02]
 
 
ACTRN12621001063808: A randomised control trial to evaluate the reactions of co-administration of influenza and COVID-19 vaccines

Suspended
4
1000
 
Sydney Local Health District, Sydney Local Health District, Snow Medical Research Foundation
Influenza, COVID-19
 
 
2022-004118-12: Concomitant administration of the Novavax vaccine and a 20-valent pneumococcal conjugate vaccine in adults aged ≥60 years

Not yet recruiting
4
256
Europe
NVX-CoV2373, pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), EMEA/H/C/005451, Suspension for injection, Solution for injection/infusion, Nuvaxovid, Apexxnar
Medical University of Vienna, Novavax INC.
Vaccination is a key strategy for preventing respiratory illnesses. Pneumococcal vaccination is recommended for all adults (age over 60 or 65 years). Given their wide application, co-administration of pneumococcal and Covid-19 vaccines may support broad population-wide coverage. However, it is unclear whether the co-administration of the Novavax (NVX) vaccine and a 20-valent pneumococcal conjugate vaccine (PCV20) results in lower immunogenicity than the administration of either alone., Vaccination is a well known tool for preventing diseases, therefore the pneumococcal vaccination is recommended for all adults., Body processes [G] - Immune system processes [G12]
 
 
PRIBIVAC, NCT05142319: Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity []

Completed
4
326
RoW
Homologous mRNA booster vaccine, Heterologous mRNA booster vaccine, COVAXIN, Nuvaxovid
Tan Tock Seng Hospital, A*Star, KK Women's and Children's Hospital, Duke-NUS Graduate Medical School
COVID-19
06/23
05/24
BEEHIVE, NCT06065176: The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection

Completed
4
1188
US
Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
Sarang K. Yoon, DO, MOH, Westat, Novavax
COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection, Upper Respiratory Disease
09/24
09/24
SHIELD, NCT06633835: Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States

Active, not recruiting
4
660
US
protein subunit: Novavax COVID-19 vaccine, 2024-25 COVID-19 vaccination, Pfizer mRNA COVID-19 vaccine, 2024-2025 formula
Novavax, University of Utah
COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection
06/25
08/25
NCT07051031: COVID-19 Reactogenicity

Not yet recruiting
4
1000
US
Nuvaxovid (NVX-CoV2705), Pfizer-BioNTech COVID-19 vaccine
Marcel Curlin
Compare Post Vaccination Reactions
04/27
06/28
NCT04583995 / 2020-004123-16: A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom

Completed
3
15185
Europe
SARS-CoV-2 rS/Matrix M1-Adjuvant, NVX-CoV2373, Placebo, Sodium chloride 0.9% (BP, sterile), Licensed seasonal influenza vaccine
Novavax
SARS-CoV-2 Infection, COVID-19
03/22
03/22
NCT05299359: A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Completed
3
150
Japan
TAK-019
Takeda
Coronavirus Disease (COVID-19)
06/22
10/23
NCT05372588: Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines

Completed
3
1340
RoW
NVX-CoV2515, Omicron BA.1 SARS-CoV-2 rS /Matrix-M Adjuvant, NVX-Cov2373, SARS-CoV-2 rS/Matrix-M Adjuvant, NVX-CoV2373 + NVX-CoV2515, Prototype/BA.1 Bivalent Vaccine, NVX-CoV2540, Omicron BA.5 SARS-CoV-2 rS /Matrix-M Adjuvant, NVX-CoV2373 + NVX-CoV2540, Prototype/BA.5 Bivalent Vaccine
Novavax
COVID-19, SARS CoV 2 Infection
07/22
04/24
NCT05433285: Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine

Completed
3
4050
RoW
COVID-19 Protein Subunit Recombinant Vaccine, Active Comparator
PT Bio Farma, Fakultas Kedokteran Universitas Indonesia, Faculty of Medicine Universitas Diponegoro, Faculty of Medicine Universitas Andalas, Faculty of Medicine Universitas Hassanudin
COVID-19
08/22
08/23
NCT04611802: A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

Completed
3
33000
US, RoW
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), NVX-CoV2373, Placebo (Initial Vaccination Period), Sodium chloride 0.9% (BP, sterile), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)
Novavax, Department of Health and Human Services
SARS-CoV Infection, Covid19
04/23
12/23
NCT05249816: Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine

Completed
3
1000
RoW
NVX-CoV2373, Novavax, BBIBP-CorV vaccine, Sinopharm BBIBP-CorV
Cogna Technology Solutions LLC, Novavax
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
05/23
05/23
NCT05546502: Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children

Completed
3
1050
RoW
SARS-CoV-2 Protein Subunit Recombinant Vaccine, Active Comparator
PT Bio Farma, Center for Child Health Universitas Gadjah Mada (CCH-PRO UGM, Cipto Mangunkusumo Hospital/Department of Child Health, Faculty of Medicine, University of Indonesia, Jakarta, Faculty of Medicine, Andalas University
Vaccine Reaction, Vaccine Adverse Reaction
12/23
01/24
NCT05875701: Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines

Completed
3
147
US
NVX-CoV2373, SARS-CoV-2 rS/Matrix-M Adjuvant, SARS-CoV-2 rS antigen/Matrix-M Adjuvant, Updated Novavax COVID-19 vaccine
Novavax
COVID-19
11/23
11/23
NCT05973006: Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines

Completed
3
400
US
NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, NVX-CoV2601, Prototype/XBB.1.5 Bivalent Vaccine (5 µg), Omicron XBB.1.5 (sub-variant)SARS-CoV-2 rS /Matrix-M Adjuvant
Novavax
COVID-19
04/24
09/24
NCT06291857: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

Active, not recruiting
3
9320
RoW
CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, COVID-19 and influenza combination, Novavax COVID-19 Vaccine, Novavax SARS-CoV-2 rS vaccine, tNIV Vaccine, Trivalent Nanoparticle Influenza Hemagglutinin Vaccine, Fluzone High Dose, Fluzone HD
Novavax
COVID-19
05/25
02/26
NCT05468736: Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

Active, not recruiting
2/3
3600
Europe, US, RoW
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), NVX-CoV2373, Placebo, Sodium chloride 0.9% (BP, sterile)
Novavax
COVID-19
01/24
10/25
NCT05925127: Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines

Completed
2/3
994
US
NVX-CoV2373 (5μg), NVX-CoV2601 (5μg), Omicron XBB.1.5, NVX-CoV2601(5μg), NVX-CoV2601 (35μg), NVX-CoV2601(35μg), NVX-CoV2601(50μg), Bivalent BA.4/5, Omicron Subvariant/Prototype Licensed mRNA Vaccine
Novavax
COVID-19
05/24
05/24
NCT05975060: A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

Completed
2/3
660
US
XBB.1.5 Vaccine (Booster), Omicron sub variant XBB.1.5 vaccine( booster) SARS-CoV-2 rS /Matrix-M Adjuvant, XBB.1.5 Vaccine (single dose), Omicron sub variant XBB.1.5 vaccine(single dose) SARS-CoV-2 rS /Matrix-M Adjuvant
Novavax
COVID-19
11/23
05/24
NCT06482359: Lot Consistency Study of COVID-19 and Influenza Combination Vaccine

Withdrawn
2/3
1925
NA
coformulated CIC Vaccine, SARS-CoV-2 rS, tNIV, Matrix-M adjuvant, Fluzone HD trivalent
Novavax
COVID-19, Influenza
11/25
05/26
NCT05112848: A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)

Completed
2
384
RoW
NVX-CoV2373, Monovalent SARS-CoV-2 rS vaccine premixed with Matrix-M adjuvant
Novavax
SARS-CoV-2 Infection
05/22
11/22
CoviCompMali, NCT05409261: Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine

Active, not recruiting
2
200
RoW
Ad26.COV2.S, Janssen, Johnson&Johnson
ANRS, Emerging Infectious Diseases, CEPI, Innovative clinical research network in vaccinology (IREIVAC), Institut National de la Santé Et de la Recherche Médicale, France, APHP, Center for Vaccine Development - Mali
COVID-19, Vaccine Reaction, SARS CoV 2 Infection, Vaccine Adverse Reaction
09/22
03/25
NCT05519839: A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine

Completed
2
1579
RoW
qNIV Vaccine with Matrix-M Adjuvant, Influenza Vaccine, CIC Vaccine with Matrix-M Adjuvant, Placebo Comparator, SARS-CoV-2 rS Vaccine with Matrix-M Adjuvant
Novavax
COVID-19, Influenza
07/23
12/23
NCT06027229: Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations

Completed
2
21
US
NVX-CoV2372, Novavax COVID-19 Vaccine
University of Wisconsin, Madison, Novavax
Immunosuppression, COVID-19
04/24
09/24
NCT05775887: A FIRST IN HUMAN TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF SARS-CoV-2 UQSC2 VACCINE IN HEALTHY ADULTS.

Completed
1
70
RoW
UQSC2 Vaccine, NVX-CoV2373 vaccine
The University of Queensland, Coalition for Epidemic Preparedness Innovations
COVID-19
12/23
12/23
NCT04832932: The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes

Active, not recruiting
N/A
2000
Europe, US, RoW
COVID-19 vaccines, BNT162b2, mRNA-1273, JNJ-78436735, AZD1222, Gam-KOVID-Vak, CoronaVac/Sinovac, BBIBP-CorV, BBV152, NVX-CoV2373
Mebo Research, Inc., Aurametrix
COVID-19 Vaccines
01/23
01/25
NCT04834869: COVID-19 Vaccines Safety Tracking (CoVaST)

Recruiting
N/A
30000
Europe, Canada, US, RoW
BNT162b2, mRNA-1273, AZD1222, CoronaVac, Sinopharm, Gam-COVID-Vac, JNJ-78436735, CVnCoV, NVX-CoV2373, BBV152
Masaryk University
Adverse Reaction to Vaccine, COVID19 Vaccine
12/25
12/26
RBD SARS-CoV-2 HBsAg VLP Vaccine / SpyBiotech, Serum Institute of India, Dynavax
ACTRN12620001308987: A Phase 1/2 randomized, placebo-controlled, multi-centre study to evaluate the safety and immunogenicity of a novel Receptor Binding Domain (RBD) COVID-19 Vaccine in Healthy Adults

Terminated
1/2
255
 
Accelagen Pty Ltd, Serum Institute of India Pvt Ltd
SARS-CoV-2, COVID-19
 
 
Hexasiil (DTwP–HepB-IPV-Hib) / Serum Institute of India
NCT06413121: Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV

Recruiting
3
1557
RoW
Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV, Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPV
Serum Institute of India Pvt. Ltd.
Diptheria Immunization, Tetanus Immunization, Pertussis Immunization, Hepatitis B Immunization, Haemophilus Influenzae Type B Immunization, Polio Immunization
08/25
05/26
tetanus/diphtheria/pertussis booster vaccine (Tdap-1018) / Dynavax
ACTRN12620001177943p: A study to evaluate the safety and tolerability of Tetanus/Diptheria/Pertussis Booster Vaccine compared to a licensed Tdap vaccine in Healthy Volunteers between 10 - 22 years of age

Not yet recruiting
1
274
 
Dynavax Technologies Corporation, Dynavax Technologies Corporation
Pertussis; Diptheria; Tetanus
 
 
ACTRN12620001177943: A study to evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Tetanus/Diphtheria/Pertussis Booster Vaccine (Tdap-1018) Compared to Boostrix in Healthy Volunteers Between 10 and 22 Years of Age

Completed
1
138
 
Dynavax Technologies Corporation, Dynavax Technologies Corporation
Pertussis, Diptheria, Tetanus
 
 
ACTRN12624000233527: Extension study of DV2-TDAP-01 to assess immunogenicity of Tdap-1018 to pertussis antigens.

Completed
N/A
57
 
Dynavax Technologies Corporation, Dynavax Technologies Corporation
Pertussis, Diptheria, Tetanus
 
 
SII-YFV / Serum Institute of India
NCT05421611: A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL

Completed
3
1824
RoW
STAMARIL, SII-YFV
Serum Institute of India Pvt. Ltd.
Yellow Fever
05/24
05/24
NCT05447377: A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants

Recruiting
3
2216
RoW
SII Yellow Fever Vaccine, STAMARIL®
Serum Institute of India Pvt. Ltd.
Yellow Fever
01/24
01/24
Cervavac (recombinant human papillomavirus recombinant quadrivalent vaccine, human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine) / Serum Institute of India
NCT06281119: Clinical Study to Evaluate SIIPL QHPV Vaccine (CERVAVAC®) in Women Living with HIV Aged 15-25 Years

Not yet recruiting
3
450
RoW
Cervavac as three dose regimen, Cervavac as two dose regimen, Gardasil as three dose regimen
Serum Institute of India Pvt. Ltd., Bill and Melinda Gates Foundation
Human Papillomavirus Infection
06/26
12/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ErepoXen (polysialylated erythropoietin) / Xenetic Biosci, Serum Institute of India, Pharmsynthez
ACTRN12613000504718: Dose finding study for Polysialylated Erythropoietin (PSA-EPO) in Chronic Kidney Disease (CKD) subjects

Recruiting
2
90
 
Xenetic Biosciences PLC, Xenetic Biosciences PLC
Anaemia in Chronic Kidney Disease
 
 
ErepoXen1: Dose finding study for Polysialylated Erythropoietin (PSA-EPO) in Chronic Kidney Disease (CKD) subjects

Recruiting
2
90
Australia, New Zealand
ErepoXen (polysialylated erythropoietin)
Xenetic Biosciences
Chronic Kidney Disease
 
 
R-vac (rubella vaccine) / Serum Institute of India
NCT06879327: Infant Malaria Vaccine Schedule Optimization

Recruiting
2
1200
RoW
R21 Matrix-M (R21/MM) Malaria Vaccine, Placebo, Hexavalent Vaccine, HEXASIIL, Pneumococcal Polysaccharide Conjugate Vaccine, PNEUMOSIL, Rotavirus, Live Attenuated (Oral) Vaccine, ROTASIIL, Measles and Rubella Vaccine, Meningococcal A conjugate vaccine, MenAfriVac, Yellow Fever vaccine, Typhoid Conjugate vaccine
PATH, Serum Institute of India PVT LTD (SII), Agilis, Pharmassist Ltd, MCT-CRO, Cytespace
Malaria Vaccines
11/27
11/27
Tetanus Antitoxin / Serum Institute of India
2019-002706-46: A Clinical Study to Assess the Safety and Immunogenicity of the Tetanus, Diphtheria and Pertussis Vaccine SIIPL Tdap in Comparison with Boostrix® in Healthy Adults, Adolescents and Children

Not yet recruiting
2/3
1332
Europe
SIIPL Tdap, Tdap, Suspension for injection in pre-filled syringe, Boostrix
Vakzine Projekt Management GmbH, Serum Institute of India Pvt. Ltd.
Active booster immunization against tetanus, diphtheria and pertussis, The vaccine is given to healthy individuals to prevent the tetanus, diphtheria and whooping cough diseases, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
ACTRN12620000848909: A Clinical Trial to Assess the safety and immunogenicity of a combined Tetanus, Diphtheria, Acellular Pertussis and Poliomyelitis Vaccine (SIIPL Tdap-IPV) compared with Boostrix-IPV in Healthy Adults, Adolescents and Children

Terminated
1/2
204
 
Serum Institute of India Pvt Ltd, Serum Institute of India Pvt Ltd
Tetanus, Diphtheria, Pertussis, Polio
 
 
Tresivac (measles, mumps & rubella vaccine live) / Serum Institute of India
MEQ00064, NCT05794230: Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa

Active, not recruiting
3
1528
RoW
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, MenACYW conjugate vaccine - MenQuadfi™, Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Menactra®, Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV), BIOPOLIO® B1/3, Pneumoccocal Vaccine, Prevnar 13®, Measles, Mumps, and Rubella Vaccine live (MMR), TRESIVAC® PFS, DTwP-HepB-Hib-IPV vaccine, EasySix™, DTaP-IPV-Hib-HepB vaccine, Hexaxim®, Hepatitis A vaccine, Biovac®-A, Rotavirus vaccine, RotaTeq®, Typhoid conjugate vaccine (TCV), Typbar TCV®, Measles vaccine, MeasBio®, Varicella vaccine live, VARIPED®, ONVARA®, OMZYTA®, Avaxim® 80 U Pediatric
Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation, Healthy Volunteers
12/25
12/25
MenAfriVac (meningococcal A conjugate vaccine) / Serum Institute of India
NCT03746665: Maternal Immunization With MenAfriVac™

Active, not recruiting
3
200
RoW
meningococcal serogroup A conjugate vaccine, MenAfriVac™.
London School of Hygiene and Tropical Medicine, Public Health England, Department of State for Health and Social Welfare, The Gambia, World Health Organization, University of Cambridge, Stanford University
Meningitis, Meningococcal
10/20
08/21
VPM1002 / SAKK, Serum Institute of India
NCT04387409 / 2020-001376-15: Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic

Active, not recruiting
3
59
Europe
VPM1002, Placebo
Vakzine Projekt Management GmbH, FGK Clinical Research GmbH
Infection, Respiratory Tract
05/21
05/21
VPM1002, NCT04351685: Evaluation of Efficacy and Safety of in Comparison to BCG in Prevention of Tb Infection in Infants

Completed
3
6940
RoW
VPM1002, BCG SII
Serum Institute of India Pvt. Ltd., Vakzine Projekt Management GmbH
Mycobacterium Tuberculosis Infection
10/24
10/24
NCT03152903: Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence

Completed
2/3
2000
RoW
VPM1002 (Recombinant BCG Vaccine), Placebo
Serum Institute of India Pvt. Ltd.
Prevention of TB Recurrence
12/23
12/23
SAKK 06/19, NCT04630730: Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Active, not recruiting
2
46
Europe
Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC), VPM1002BC, Atezolizumab, Tecentriq™, Cisplatin, Platinol®, Gemcitabine, Gemzar ®
Swiss Group for Clinical Cancer Research
Bladder Cancer
06/26
06/30
SAKK 06/14, NCT02371447 / 2014-005330-58: VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer

Completed
1/2
39
Europe
VPM1002BC, Mycobacterium bovis BCG∆ureC::Hly+, VPM1002
Swiss Group for Clinical Cancer Research
Bladder Cancer
10/19
03/23
NCT05539989: Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa

Withdrawn
1/2
480
RoW
VPM1002 Vaccine, BCG Vaccine, Placebo
International Maternal Pediatric Adolescent AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH)
Tuberculosis, HIV Infections
07/27
07/27
NeuCeptin (trastuzumab biosimilar) / NeuClone, Serum Institute of India
ACTRN12618001657213: A clinical trial to compare the rate of blood clearance and safety of a biosimilar, to the original Herceptin drug, in healthy male volunteers.

Active, not recruiting
1
111
 
NeuClone Pty Ltd, NeuClone Pty Ltd
Her2 positive breast cancer, Her2 positive gastric cancer
 
 
NeuLara (ustekinumab biosimilar) / NeuClone, Serum Institute of India
ACTRN12619001473156: A Phase 1 Single Dose Study to Assess the Pharmacokinetics and Safety of the Biosimilar Ustekinumab Healthy Volunteers

Recruiting
1
210
 
NeuClone Proprietary Limited, NeuClone Proprietary Limited
Plaque Psoriasis
 
 
meningococcal groups ACYWX conjugate vaccine (NmCV-5) / PATH, Serum Institute of India
NCT05093829: Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine

Completed
3
1325
RoW
NmCV-5, MenACWY-TT, Nimenrix
Emory University, National Institute of Allergy and Infectious Diseases (NIAID)
Meningitis
03/23
02/25
NCT05739292: Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old

Completed
1
60
RoW
EuNmCV-5, Meningococcal(Groups A, C, W-135, X, and Y) Conjugate Vaccine, Menveo, Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine
EuBiologics Co.,Ltd
Infection, Meningococcal
05/23
10/23
R21/Matrix-M / University of Oxford, Serum Institute of India
IMVACS, NCT06860178: Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa

Not yet recruiting
4
40000
RoW
Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months
Epicentre, R-Evolution Worldwide, CNRST Burkina Faso, USTTB Mali, Liverpool School of Tropical Medicine
Malaria Vaccine
05/26
12/27
COSAV-R21, NCT07038837: Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in Chad

Not yet recruiting
4
70000
RoW
"Synchronised" arm (intervention)
Epicentre, Epicentre, Paris, France., Chad Ministry of Public Health Expanded Programme on Immunisation (EPI), Chad Ministry of Public Health National Malaria Control Programme (NMCP), Liverpool School of Tropical Medicine
Malaria Infection, Malaria Vaccines
12/26
06/28
MVDA, NCT06068530: Mass Vaccine and Drug Administration, Bangladesh

Recruiting
4
10000
RoW
DHA/piperaquine and a SLD-PQ, Study vaccine R21/Matrix-M™
University of Oxford
Plasmodium Falciparum Malaria
02/28
02/28
NCT04704830: R21/Matrix-M in African Children Against Clinical Malaria

Active, not recruiting
3
4800
Europe
R21/Matrix-M, Rabies vaccine or Hepatitis A vaccine
University of Oxford, Institut de Recherche en Sciences de la Sante - Clinical Research Unit of Nanoro (IRSS-URCN), Nanoro, Burkina Faso, Institut de Recherche en Sciences de la Sante-Direction Regionale de l'Ouest, Malaria Research and Training Center, Bamako, Mali, KEMRI-Wellcome Trust Collaborative Research Program, Ifakara Health Institute Clinical Trial Facility, Bagamoyo Research and Training Centre, PO Box 74, Bagamoyo, Tanzania, London School of Hygiene and Tropical Medicine
Malaria
03/23
03/26
2018-004391-34: A clinical trial to assess the safety, immune response, and protection against infection of novel malaria vaccines.

Not yet recruiting
2
82
Europe
R21, Matrix-M, Solution for injection
University of Oxford
Plasmodium falciparum infection, Malaria, Diseases [C] - Parasitic Diseases [C03]
 
 
NCT03947190: A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults

Terminated
2
80
RoW
R21/Matrix-M, ChAd63/MVA ME-TRAP, intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge
University of Oxford, Kenya Medical Research Institute, European and Developing Countries Clinical Trials Partnership (EDCTP)
Malaria,Falciparum
02/23
02/23
R21/Matrix-M, NCT05252845: Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults

Completed
2
127
RoW
R21/Matrix-M vaccination, DHA-PIP, PQ
University of Oxford
Malaria,Falciparum
06/23
09/23
NCT03896724: Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso

Completed
1/2
450
RoW
R21 adjuvanted with 25mcg Matrix-M, Rabies Vaccine, R21 adjuvanted with 50mcg Matrix-M
University of Oxford, Institut de Recherche en Sciences de la Sante - Clinical Research Unit of Nanoro (IRSS-URCN), European and Developing Countries Clinical Trials Partnership (EDCTP)
Malaria,Falciparum
07/23
07/23
NCT05155579: Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

Active, not recruiting
1
590
Europe, RoW
R21/Matrix-M - single vial formulation, R21/Matrix-M - two vial formulation, Licensed vaccine - Measles-rubella, Licensed vaccine - Yellow fever, Licensed vaccine - Pentavalent (diphtheria, tetanus, pertussis, hepatitis B and Hib), Licensed vaccine - Oral Polio Vaccine (OPV), Licensed vaccine - Rotavirus, Licensed vaccine - Pneumococcal vaccine, Licensed vaccine - Inactivated Polio Vaccine (IPV)
University of Oxford, Malaria Research and Training Center, Bamako, Mali
Malaria
05/25
05/25
NCT06320535: A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™

Recruiting
1
36
Europe
R21/Matrix M™ (Group 1), R21/Matrix M™ (Group 2), R21/Matrix M™ (Group 3), Fine needle aspiration (FNA)
University of Oxford, Bill and Melinda Gates Foundation, University Hospitals Bristol and Weston NHS Foundation Trust
Malaria,Falciparum
06/26
06/27
NCT05385510: Assessment of Safety and Immunogenicity of R21/Matrix-M™ in African Children Living With HIV

Active, not recruiting
1
120
RoW
R21/Matrix-M™
University of Oxford, MRC/UVRI and LSHTM Uganda Research Unit
Malaria
09/25
09/25
NCT06507605: Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults

Active, not recruiting
1
240
RoW
R21, Pfs230D1-CRM197, Pfs230D1-EPA, Matrix-M
Serum Institute of India Pvt. Ltd., National Institute of Allergy and Infectious Diseases (NIAID)
Prevention of Malaria Transmission and Clinical Malaria
10/25
10/25
VAC093, NCT06958198: A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)

Not yet recruiting
1
56
RoW
R21, RH5.1, R78C, Matrix-M™
University of Oxford, Institut de Recherche en Sciences de la Sante, Burkina Faso, European and Developing Countries Clinical Trials Partnership (EDCTP), Wellcome Trust
Malaria,Falciparum
10/26
10/26
NCT05357560: A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21

Active, not recruiting
1
107
RoW
Matrix-M with RH5.2 VLP and/or R21
University of Oxford, European and Developing Countries Clinical Trials Partnership (EDCTP), Medical Research Council Unit, The Gambia
Malaria, Plasmodium Falciparum
06/25
06/25
NCT07009847: An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine

Not yet recruiting
N/A
2308
RoW
Case control study of clinical malaria, Case control study of severe malaria, Case control study of death (all cause)
Serum Institute of India Pvt. Ltd.
Malaria,Falciparum, Morality
10/26
12/26
Pneumosil (10-valent pneumococcal conjugate vaccine) / Serum Institute of India
FPCV, NCT03489018: The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants

Completed
4
2100
RoW
PCV10, Synflorix (GlaxoSmithKline plc.), 10-valent pneumococcal conjugate vaccine, PCV13, Prevnar 13 (Pfizer Inc.), 13-valent pneumococcal conjugate vaccine, Prevnar13
London School of Hygiene and Tropical Medicine, University College, London, KEMRI-Wellcome Trust Collaborative Research Program, Bill and Melinda Gates Foundation, National Institute of Health Research (NIHR) Mucosal Pathogens Research Unit (MPRU), Wellcome Trust
Pneumococcal Infection, Streptococcus Pneumoniae Infection, Invasive Pneumococcal Disease, Protection Against
09/22
11/24
fPCV, NCT05175014: Mass Campaigns With Fractional Dose Pneumococcal Vaccines in Sub-Saharan Africa

Completed
4
44618
RoW
PCV10 full dose, PCV10 fractional dose
Epicentre, LSHTM, Kenya Medical Research Institute, Universite Abdou Moumouni de Niamey, Niger
Pneumococcal Carriage
03/23
10/23
OPTIMAL, NCT06817421: Opportunistic Pneumococcal Immunisation Trial in MALnutrition

Not yet recruiting
4
264
RoW
Pneumococcal conjugate vaccine, Typhoid conjugate vaccine
Nick Fancourt, Murdoch Childrens Research Institute, The University of Western Australia, University of Edinburgh, Timor-Leste Ministry of Health
Severe Acute Malnutrition in Childhood, Pneumococcal Disease, Pneumococcal Vaccines, Pneumococcal Infection, Pneumonia in Children
12/27
02/29
NCT06116591: A Phase 2 Study to Learn About a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers

Completed
2
105
Europe
mPnC candidate, mPnC control
Pfizer
Healthy Participants
05/24
05/24
PNEUMOSIL, NCT05140720: Assess the Safety and Immunogenicity of ® Vaccine in Healthy Vietnamese Children, 6 Weeks to 24 Months of Age

Not yet recruiting
N/A
300
NA
PNEUMOSIL®
Vabiotech, Vietstar Biomedical Research
Streptococcus Pneumonia, Vaccine Preventable Disease
02/22
06/22
PCV1+1_FU, NCT04275284: Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children

Completed
N/A
600
RoW
PCV10, Synflorix, PCV13, Prevnar13
University of Witwatersrand, South Africa
Pneumonia, Meningitis
12/22
12/22
Covovax (NVX-CoV2373) / Novavax, Serum Institute of India
ACTRN12622000238774: A randomised trial to evaluate the immune response of COVID-19 vaccines in adults and adolescents

Recruiting
4
1325
 
The Kids Research Institute Australia, National Health and Medical Research Council (NHMRC), Snow Medical Research Foundation
COVID-19
 
 
2022-000905-29: Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after treatment with monoclonal antibodies Cinetica tempoRale dei marcatori di risposta anticorpale e cEllulare e relativo impatto della rivacciNazione in pazienti guariti dalla COVID-19 dopo trattamento con anticoRpi monoclonali

Not yet recruiting
4
150
Europe
Evusheld, Xevudy, Comirnaty, Spikevax, Nuvaxovid, [-], Solution for injection, Concentrate for solution for infusion, Dispersion for injection, Evusheld, Xevudy, Comirnaty, Spikevax, Nuvaxovid
ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI"
Covid-19 infection Infezione da Covid-19, Covid-19 infection Infezione da Covid-19, Diseases [C] - Virus Diseases [C02]
 
 
ACTRN12621001063808: A randomised control trial to evaluate the reactions of co-administration of influenza and COVID-19 vaccines

Suspended
4
1000
 
Sydney Local Health District, Sydney Local Health District, Snow Medical Research Foundation
Influenza, COVID-19
 
 
2022-004118-12: Concomitant administration of the Novavax vaccine and a 20-valent pneumococcal conjugate vaccine in adults aged ≥60 years

Not yet recruiting
4
256
Europe
NVX-CoV2373, pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), EMEA/H/C/005451, Suspension for injection, Solution for injection/infusion, Nuvaxovid, Apexxnar
Medical University of Vienna, Novavax INC.
Vaccination is a key strategy for preventing respiratory illnesses. Pneumococcal vaccination is recommended for all adults (age over 60 or 65 years). Given their wide application, co-administration of pneumococcal and Covid-19 vaccines may support broad population-wide coverage. However, it is unclear whether the co-administration of the Novavax (NVX) vaccine and a 20-valent pneumococcal conjugate vaccine (PCV20) results in lower immunogenicity than the administration of either alone., Vaccination is a well known tool for preventing diseases, therefore the pneumococcal vaccination is recommended for all adults., Body processes [G] - Immune system processes [G12]
 
 
PRIBIVAC, NCT05142319: Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity []

Completed
4
326
RoW
Homologous mRNA booster vaccine, Heterologous mRNA booster vaccine, COVAXIN, Nuvaxovid
Tan Tock Seng Hospital, A*Star, KK Women's and Children's Hospital, Duke-NUS Graduate Medical School
COVID-19
06/23
05/24
BEEHIVE, NCT06065176: The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection

Completed
4
1188
US
Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
Sarang K. Yoon, DO, MOH, Westat, Novavax
COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection, Upper Respiratory Disease
09/24
09/24
SHIELD, NCT06633835: Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States

Active, not recruiting
4
660
US
protein subunit: Novavax COVID-19 vaccine, 2024-25 COVID-19 vaccination, Pfizer mRNA COVID-19 vaccine, 2024-2025 formula
Novavax, University of Utah
COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection
06/25
08/25
NCT07051031: COVID-19 Reactogenicity

Not yet recruiting
4
1000
US
Nuvaxovid (NVX-CoV2705), Pfizer-BioNTech COVID-19 vaccine
Marcel Curlin
Compare Post Vaccination Reactions
04/27
06/28
NCT04583995 / 2020-004123-16: A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom

Completed
3
15185
Europe
SARS-CoV-2 rS/Matrix M1-Adjuvant, NVX-CoV2373, Placebo, Sodium chloride 0.9% (BP, sterile), Licensed seasonal influenza vaccine
Novavax
SARS-CoV-2 Infection, COVID-19
03/22
03/22
NCT05299359: A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Completed
3
150
Japan
TAK-019
Takeda
Coronavirus Disease (COVID-19)
06/22
10/23
NCT05372588: Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines

Completed
3
1340
RoW
NVX-CoV2515, Omicron BA.1 SARS-CoV-2 rS /Matrix-M Adjuvant, NVX-Cov2373, SARS-CoV-2 rS/Matrix-M Adjuvant, NVX-CoV2373 + NVX-CoV2515, Prototype/BA.1 Bivalent Vaccine, NVX-CoV2540, Omicron BA.5 SARS-CoV-2 rS /Matrix-M Adjuvant, NVX-CoV2373 + NVX-CoV2540, Prototype/BA.5 Bivalent Vaccine
Novavax
COVID-19, SARS CoV 2 Infection
07/22
04/24
NCT05433285: Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine

Completed
3
4050
RoW
COVID-19 Protein Subunit Recombinant Vaccine, Active Comparator
PT Bio Farma, Fakultas Kedokteran Universitas Indonesia, Faculty of Medicine Universitas Diponegoro, Faculty of Medicine Universitas Andalas, Faculty of Medicine Universitas Hassanudin
COVID-19
08/22
08/23
NCT04611802: A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

Completed
3
33000
US, RoW
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), NVX-CoV2373, Placebo (Initial Vaccination Period), Sodium chloride 0.9% (BP, sterile), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)
Novavax, Department of Health and Human Services
SARS-CoV Infection, Covid19
04/23
12/23
NCT05249816: Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine

Completed
3
1000
RoW
NVX-CoV2373, Novavax, BBIBP-CorV vaccine, Sinopharm BBIBP-CorV
Cogna Technology Solutions LLC, Novavax
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
05/23
05/23
NCT05546502: Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children

Completed
3
1050
RoW
SARS-CoV-2 Protein Subunit Recombinant Vaccine, Active Comparator
PT Bio Farma, Center for Child Health Universitas Gadjah Mada (CCH-PRO UGM, Cipto Mangunkusumo Hospital/Department of Child Health, Faculty of Medicine, University of Indonesia, Jakarta, Faculty of Medicine, Andalas University
Vaccine Reaction, Vaccine Adverse Reaction
12/23
01/24
NCT05875701: Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines

Completed
3
147
US
NVX-CoV2373, SARS-CoV-2 rS/Matrix-M Adjuvant, SARS-CoV-2 rS antigen/Matrix-M Adjuvant, Updated Novavax COVID-19 vaccine
Novavax
COVID-19
11/23
11/23
NCT05973006: Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines

Completed
3
400
US
NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, NVX-CoV2601, Prototype/XBB.1.5 Bivalent Vaccine (5 µg), Omicron XBB.1.5 (sub-variant)SARS-CoV-2 rS /Matrix-M Adjuvant
Novavax
COVID-19
04/24
09/24
NCT06291857: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

Active, not recruiting
3
9320
RoW
CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, COVID-19 and influenza combination, Novavax COVID-19 Vaccine, Novavax SARS-CoV-2 rS vaccine, tNIV Vaccine, Trivalent Nanoparticle Influenza Hemagglutinin Vaccine, Fluzone High Dose, Fluzone HD
Novavax
COVID-19
05/25
02/26
NCT05468736: Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

Active, not recruiting
2/3
3600
Europe, US, RoW
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), NVX-CoV2373, Placebo, Sodium chloride 0.9% (BP, sterile)
Novavax
COVID-19
01/24
10/25
NCT05925127: Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines

Completed
2/3
994
US
NVX-CoV2373 (5μg), NVX-CoV2601 (5μg), Omicron XBB.1.5, NVX-CoV2601(5μg), NVX-CoV2601 (35μg), NVX-CoV2601(35μg), NVX-CoV2601(50μg), Bivalent BA.4/5, Omicron Subvariant/Prototype Licensed mRNA Vaccine
Novavax
COVID-19
05/24
05/24
NCT05975060: A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

Completed
2/3
660
US
XBB.1.5 Vaccine (Booster), Omicron sub variant XBB.1.5 vaccine( booster) SARS-CoV-2 rS /Matrix-M Adjuvant, XBB.1.5 Vaccine (single dose), Omicron sub variant XBB.1.5 vaccine(single dose) SARS-CoV-2 rS /Matrix-M Adjuvant
Novavax
COVID-19
11/23
05/24
NCT06482359: Lot Consistency Study of COVID-19 and Influenza Combination Vaccine

Withdrawn
2/3
1925
NA
coformulated CIC Vaccine, SARS-CoV-2 rS, tNIV, Matrix-M adjuvant, Fluzone HD trivalent
Novavax
COVID-19, Influenza
11/25
05/26
NCT05112848: A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)

Completed
2
384
RoW
NVX-CoV2373, Monovalent SARS-CoV-2 rS vaccine premixed with Matrix-M adjuvant
Novavax
SARS-CoV-2 Infection
05/22
11/22
CoviCompMali, NCT05409261: Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine

Active, not recruiting
2
200
RoW
Ad26.COV2.S, Janssen, Johnson&Johnson
ANRS, Emerging Infectious Diseases, CEPI, Innovative clinical research network in vaccinology (IREIVAC), Institut National de la Santé Et de la Recherche Médicale, France, APHP, Center for Vaccine Development - Mali
COVID-19, Vaccine Reaction, SARS CoV 2 Infection, Vaccine Adverse Reaction
09/22
03/25
NCT05519839: A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine

Completed
2
1579
RoW
qNIV Vaccine with Matrix-M Adjuvant, Influenza Vaccine, CIC Vaccine with Matrix-M Adjuvant, Placebo Comparator, SARS-CoV-2 rS Vaccine with Matrix-M Adjuvant
Novavax
COVID-19, Influenza
07/23
12/23
NCT06027229: Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations

Completed
2
21
US
NVX-CoV2372, Novavax COVID-19 Vaccine
University of Wisconsin, Madison, Novavax
Immunosuppression, COVID-19
04/24
09/24
NCT05775887: A FIRST IN HUMAN TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF SARS-CoV-2 UQSC2 VACCINE IN HEALTHY ADULTS.

Completed
1
70
RoW
UQSC2 Vaccine, NVX-CoV2373 vaccine
The University of Queensland, Coalition for Epidemic Preparedness Innovations
COVID-19
12/23
12/23
NCT04832932: The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes

Active, not recruiting
N/A
2000
Europe, US, RoW
COVID-19 vaccines, BNT162b2, mRNA-1273, JNJ-78436735, AZD1222, Gam-KOVID-Vak, CoronaVac/Sinovac, BBIBP-CorV, BBV152, NVX-CoV2373
Mebo Research, Inc., Aurametrix
COVID-19 Vaccines
01/23
01/25
NCT04834869: COVID-19 Vaccines Safety Tracking (CoVaST)

Recruiting
N/A
30000
Europe, Canada, US, RoW
BNT162b2, mRNA-1273, AZD1222, CoronaVac, Sinopharm, Gam-COVID-Vac, JNJ-78436735, CVnCoV, NVX-CoV2373, BBV152
Masaryk University
Adverse Reaction to Vaccine, COVID19 Vaccine
12/25
12/26
RBD SARS-CoV-2 HBsAg VLP Vaccine / SpyBiotech, Serum Institute of India, Dynavax
ACTRN12620001308987: A Phase 1/2 randomized, placebo-controlled, multi-centre study to evaluate the safety and immunogenicity of a novel Receptor Binding Domain (RBD) COVID-19 Vaccine in Healthy Adults

Terminated
1/2
255
 
Accelagen Pty Ltd, Serum Institute of India Pvt Ltd
SARS-CoV-2, COVID-19
 
 
Hexasiil (DTwP–HepB-IPV-Hib) / Serum Institute of India
NCT06413121: Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV

Recruiting
3
1557
RoW
Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV, Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPV
Serum Institute of India Pvt. Ltd.
Diptheria Immunization, Tetanus Immunization, Pertussis Immunization, Hepatitis B Immunization, Haemophilus Influenzae Type B Immunization, Polio Immunization
08/25
05/26
tetanus/diphtheria/pertussis booster vaccine (Tdap-1018) / Dynavax
ACTRN12620001177943p: A study to evaluate the safety and tolerability of Tetanus/Diptheria/Pertussis Booster Vaccine compared to a licensed Tdap vaccine in Healthy Volunteers between 10 - 22 years of age

Not yet recruiting
1
274
 
Dynavax Technologies Corporation, Dynavax Technologies Corporation
Pertussis; Diptheria; Tetanus
 
 
ACTRN12620001177943: A study to evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Tetanus/Diphtheria/Pertussis Booster Vaccine (Tdap-1018) Compared to Boostrix in Healthy Volunteers Between 10 and 22 Years of Age

Completed
1
138
 
Dynavax Technologies Corporation, Dynavax Technologies Corporation
Pertussis, Diptheria, Tetanus
 
 
ACTRN12624000233527: Extension study of DV2-TDAP-01 to assess immunogenicity of Tdap-1018 to pertussis antigens.

Completed
N/A
57
 
Dynavax Technologies Corporation, Dynavax Technologies Corporation
Pertussis, Diptheria, Tetanus
 
 
SII-YFV / Serum Institute of India
NCT05421611: A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL

Completed
3
1824
RoW
STAMARIL, SII-YFV
Serum Institute of India Pvt. Ltd.
Yellow Fever
05/24
05/24
NCT05447377: A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants

Recruiting
3
2216
RoW
SII Yellow Fever Vaccine, STAMARIL®
Serum Institute of India Pvt. Ltd.
Yellow Fever
01/24
01/24
Cervavac (recombinant human papillomavirus recombinant quadrivalent vaccine, human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine) / Serum Institute of India
NCT06281119: Clinical Study to Evaluate SIIPL QHPV Vaccine (CERVAVAC®) in Women Living with HIV Aged 15-25 Years

Not yet recruiting
3
450
RoW
Cervavac as three dose regimen, Cervavac as two dose regimen, Gardasil as three dose regimen
Serum Institute of India Pvt. Ltd., Bill and Melinda Gates Foundation
Human Papillomavirus Infection
06/26
12/26

Download Options